Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
By E. Eerenberg, P. Kamphuisen, M. Sijpkens, J. Meijers, H. Buller, M. Levi. Circulation, 2011
1,468 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine
View Paper: https://www.semanticscholar.org/paper/ea8aac53f35fbc89adc8e8b30c1b6a813f67c08e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- Jean-Louis Vincent
- Alejandro Rabinstein
- Hani Jneid
- Allan S. Jaffe
- Gerhard Hindricks
- R. Redberg
- Nancy R. Cook
- P. Ridker
In Hematology
Citations in the corpus
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. (2012, background): “Blood Supply, Amsterdam, the Netherlands) administered to healthy and relatively young individuals taking rivaroxaban, but no effect was seen with dabigatran.(89) Another study found that low-dose FEIBA (Baxter AG, Vienna, Austria) reversed the anticoagulant activity of rivaroxaban and dabigatran.”
- Management of bleeding and coagulopathy following major trauma: an updated European guideline (2013, neutral): “(50 U/kg) PCC treatment is inefficient [494].”
- Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “Prothrombin Complex Concentrates (PCC) The best available evidence for the efficacy of PCC in reversing the anticoagulation effect of DTIs includes animal studies [158, 175–177], trials with healthy volunteers [135, 138, 178], and in vivo investigations [168, 169, 179].”
- 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “Noninvasive stress testing is recommended in low- and intermediate-risk patients who have been free of ischemia at rest or with low-level activity for a minimum of 12 to 24 hours (179-183).”
- The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition (2016, background): “In summary, although not completely consistent, laboratory 8 coagulation tests, parameters of viscoelastic tests and of thrombin generation were (nearly) 9 normalised with high-dose treatment [611-619].”